http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 16 Oct 2026 09:11:27 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Absci+Corp.+%28ABSI%29+PT+Raised+to+%2420+at+KeyBanc/27196256.html KeyBanc analyst Scott Schoenhaus raised the price target on Absci Corp. (NASDAQ: ABSI) to $20.00 (from $16.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Absci+Corp.+%28ABSI%29+PT+Raised+to+%2420+at+KeyBanc/27196256.html Fri, 16 Oct 2026 09:11:27 -0400 ABSI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Absci+Corp++++++++++++++++For%3A+Oct+12++Filed+by%3A+McClain+Sean/27188159.html si-local-file:///var/storage/secattach/20261014/27188159.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Absci+Corp++++++++++++++++For%3A+Oct+12++Filed+by%3A+McClain+Sean/27188159.html Wed, 14 Oct 2026 19:16:00 -0400 ABSI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Absci+Corp++++++++++++++++For%3A+Oct+12++Filed+by%3A+Bedrick+Todd/27188158.html si-local-file:///var/storage/secattach/20261014/27188158.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Absci+Corp++++++++++++++++For%3A+Oct+12++Filed+by%3A+Bedrick+Todd/27188158.html Wed, 14 Oct 2026 19:16:00 -0400 ABSI http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Absci+Corp++++++++++++++++For%3A+Oct+12++Filed+by%3A+Jonasson+Zachariah/27188156.html si-local-file:///var/storage/secattach/20261014/27188156.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Absci+Corp++++++++++++++++For%3A+Oct+12++Filed+by%3A+Jonasson+Zachariah/27188156.html Wed, 14 Oct 2026 19:15:00 -0400 ABSI http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Press+Releases/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html <p align="left"><em>News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.</em></p> <p align="left">BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7sXGtBEbCaC4m9foPtvaehp2dM0OL5Fz8rrcDgG8FOMzwyvE8-jFRvN8itbPvnz7JRmsycCELE7iSNXv29rpb2rTv-zk1gFtswJYPB5ZptOMjJPpmmpFzoYRSZTg9gQ" rel="nofollow" target="_blank"><em>Biotech Insider</em></a><em> News Commentary</em> - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies http://www.streetinsider.com/Globe+Newswire/AI-Designed+Biologics+Are+Moving+From+the+Screen+to+the+Bench%2C+and+Developers+Are+Hiring+for+the+Next+Test/27185197.html Wed, 14 Oct 2026 09:45:00 -0400 ABSI GENB HYFT MRNA SNY http://www.streetinsider.com/Press+Releases/Absci+to+Report+Business+Updates+and+Third+Quarter+2026+Financial+and+Operating+Results+on+November+12%2C+2026/27177254.html <p align="left">VANCOUVER, Wash. and NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the third quarter 2026 before market open on Thursday, November 12, 2026.</p> <p align="justify">Absci management will webcast a corresponding conference call beginning at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook.</p> <p align="justify">Live audio of the webcast will be available on the company’s investor http://www.streetinsider.com/Press+Releases/Absci+to+Report+Business+Updates+and+Third+Quarter+2026+Financial+and+Operating+Results+on+November+12%2C+2026/27177254.html Tue, 13 Oct 2026 08:00:00 -0400 ABSI http://www.streetinsider.com/Globe+Newswire/Absci+to+Report+Business+Updates+and+Third+Quarter+2026+Financial+and+Operating+Results+on+November+12%2C+2026/27177254.html <p align="left">VANCOUVER, Wash. and NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the third quarter 2026 before market open on Thursday, November 12, 2026.</p> <p align="justify">Absci management will webcast a corresponding conference call beginning at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook.</p> <p align="justify">Live audio of the webcast will be available on the company’s investor http://www.streetinsider.com/Globe+Newswire/Absci+to+Report+Business+Updates+and+Third+Quarter+2026+Financial+and+Operating+Results+on+November+12%2C+2026/27177254.html Tue, 13 Oct 2026 08:00:00 -0400 ABSI http://www.streetinsider.com/Analyst+Comments/Guggenheim+Reiterates+Buy+Rating+on+Absci+Corp.+%28ABSI%29/27108902.html <p>Guggenheim analyst Vamil Divan reiterated a Buy rating and $15.00 price target on Absci Corp. (NASDAQ: ABSI)</p><p>The analyst comments: “Absci (ABSI) this week released preliminary details for STORYLINE, its planned Phase 2 trial of ABS-201 in endometriosis, and pushed the expected start to mid-2027 from 4Q 2026, so we believe data may now come in 2028. In our follow up call, management attributed the later start mainly to waiting for more safety and pharmacokinetic (PK) data from HEADLINE, the ongoing trial in pattern hair loss (PHL), to properly select doses for STORYLINE. The roughly 150-patient, placebo-controlled trial would measure dysmenorrhea http://www.streetinsider.com/Analyst+Comments/Guggenheim+Reiterates+Buy+Rating+on+Absci+Corp.+%28ABSI%29/27108902.html Mon, 28 Sep 2026 01:33:30 -0400 ABSI http://www.streetinsider.com/FDA/Absci+plans+Phase+2+trial+of+ABS-201+for+endometriosis+in+mid-2027/27099093.html <p>Absci Corporation (Nasdaq: ABSI) announced details of its planned Phase 2 STORYLINE clinical trial evaluating ABS-201, an investigational anti-prolactin receptor antibody, for endometriosis, according to a press release.</p> <p>The planned trial is a double-blind, randomized, placebo-controlled study targeting participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain. Efficacy endpoints would include reductions in dysmenorrhea and non-menstrual pelvic pain, measured through patient-reported outcomes.</p> <p>Absci anticipates recruiting approximately 150 patients across 10 or more countries, subject to protocol finalization and regulatory clearance. The company expects to initiate the trial in mid-2027, with dose selection to be informed by data from its ongoing Phase http://www.streetinsider.com/FDA/Absci+plans+Phase+2+trial+of+ABS-201+for+endometriosis+in+mid-2027/27099093.html Thu, 24 Sep 2026 08:00:54 -0400 ABSI http://www.streetinsider.com/Press+Releases/Absci+Announces+Preliminary+Details+for+Phase+2+STORYLINE%E2%84%A2+Trial+of+AI-Designed+Antibody+ABS-201%E2%84%A2+for+Endometriosis/27098971.html <p align="center"><em>Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP)</em></p> <p align="center"><em>Anticipated initiation of Phase 2 trial in mid-2027</em></p> <p align="justify">VANCOUVER, Wash. and NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced additional details for the company’s planned global, multi-center Phase 2 STORYLINE clinical trial evaluating ABS-201, an investigational anti-prolactin receptor (PRLR) antibody engineered with Absci’s generative AI platform, for endometriosis.</p> <p align="justify">The planned Phase 2, double-blind, randomized, http://www.streetinsider.com/Press+Releases/Absci+Announces+Preliminary+Details+for+Phase+2+STORYLINE%E2%84%A2+Trial+of+AI-Designed+Antibody+ABS-201%E2%84%A2+for+Endometriosis/27098971.html Thu, 24 Sep 2026 08:00:00 -0400 ABSI http://www.streetinsider.com/Globe+Newswire/Absci+Announces+Preliminary+Details+for+Phase+2+STORYLINE%E2%84%A2+Trial+of+AI-Designed+Antibody+ABS-201%E2%84%A2+for+Endometriosis/27098971.html <p align="center"><em>Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP)</em></p> <p align="center"><em>Anticipated initiation of Phase 2 trial in mid-2027</em></p> <p align="justify">VANCOUVER, Wash. and NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced additional details for the company’s planned global, multi-center Phase 2 STORYLINE clinical trial evaluating ABS-201, an investigational anti-prolactin receptor (PRLR) antibody engineered with Absci’s generative AI platform, for endometriosis.</p> <p align="justify">The planned Phase 2, double-blind, randomized, http://www.streetinsider.com/Globe+Newswire/Absci+Announces+Preliminary+Details+for+Phase+2+STORYLINE%E2%84%A2+Trial+of+AI-Designed+Antibody+ABS-201%E2%84%A2+for+Endometriosis/27098971.html Thu, 24 Sep 2026 08:00:00 -0400 ABSI http://www.streetinsider.com/Press+Releases/Absci+to+Participate+in+Upcoming+Investor+Conferences/27008986.html <p align="justify">VANCOUVER, Wash. and NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor conferences:</p> <ul type="disc"><li style="text-align:justify;"><strong>H.C. Wainwright 28</strong>^{<strong>th</strong>}<strong> Annual Global Investment Conference (New York, NY)</strong><br /></li></ul> <p align="justify">Fireside chat on Tuesday, September 15^th at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time</p> <ul type="disc"><li style="text-align:justify;"><strong>Morgan Stanley 24</strong>^{<strong>th</strong>}<strong> Annual Global Healthcare Conference (New York, NY)</strong><br /></li></ul> <p align="justify">Fireside chat on Wednesday, September 16^th at 7:45 a.m. Eastern http://www.streetinsider.com/Press+Releases/Absci+to+Participate+in+Upcoming+Investor+Conferences/27008986.html Tue, 01 Sep 2026 08:00:00 -0400 ABSI http://www.streetinsider.com/Globe+Newswire/Absci+to+Participate+in+Upcoming+Investor+Conferences/27008986.html <p align="justify">VANCOUVER, Wash. and NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the following upcoming investor conferences:</p> <ul type="disc"><li style="text-align:justify;"><strong>H.C. Wainwright 28</strong>^{<strong>th</strong>}<strong> Annual Global Investment Conference (New York, NY)</strong><br /></li></ul> <p align="justify">Fireside chat on Tuesday, September 15^th at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time</p> <ul type="disc"><li style="text-align:justify;"><strong>Morgan Stanley 24</strong>^{<strong>th</strong>}<strong> Annual Global Healthcare Conference (New York, NY)</strong><br /></li></ul> <p align="justify">Fireside chat on Wednesday, September 16^th at 7:45 a.m. Eastern http://www.streetinsider.com/Globe+Newswire/Absci+to+Participate+in+Upcoming+Investor+Conferences/27008986.html Tue, 01 Sep 2026 08:00:00 -0400 ABSI http://www.streetinsider.com/Press+Releases/Most+AI+Drug+Discovery+Reads+the+Genetic+Code.+The+Next+Wave+Is+Learning+to+Read+What+the+Code+Actually+Does./26947782.html <p><strong>News Provided by USA News Group on behalf of MindWalk Holdings Corp.</strong></p><p align="left">NEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Tuhl8SoGdqXkIoZcmiFpyrNVstQDwhTHtEEDZyhvi4W7dn-jnhNRtC8cmX1UMw-F3MAMiRzcTRtl5HibqcpvgSSrc-L333VVG8_-f6NSlyo=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>Artificial intelligence has become the most talked-about tool in drug discovery, promising to compress the years and billions of dollars it takes to turn a biological insight into a medicine. But most of the AI now aimed at biology shares a hidden limitation: it reasons primarily from sequence, the raw genetic letters of DNA, RNA, and proteins. Two molecules whose sequences look alike are treated as related; two that http://www.streetinsider.com/Press+Releases/Most+AI+Drug+Discovery+Reads+the+Genetic+Code.+The+Next+Wave+Is+Learning+to+Read+What+the+Code+Actually+Does./26947782.html Wed, 19 Aug 2026 08:56:00 -0400 ABCL ABCL ABSI ABSI AZN AZN HYFT HYFT LLY LLY http://www.streetinsider.com/Globe+Newswire/Most+AI+Drug+Discovery+Reads+the+Genetic+Code.+The+Next+Wave+Is+Learning+to+Read+What+the+Code+Actually+Does./26947782.html <p><strong>News Provided by USA News Group on behalf of MindWalk Holdings Corp.</strong></p><p align="left">NEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Tuhl8SoGdqXkIoZcmiFpyrNVstQDwhTHtEEDZyhvi4W7dn-jnhNRtC8cmX1UMw-F3MAMiRzcTRtl5HibqcpvgSSrc-L333VVG8_-f6NSlyo=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>Artificial intelligence has become the most talked-about tool in drug discovery, promising to compress the years and billions of dollars it takes to turn a biological insight into a medicine. But most of the AI now aimed at biology shares a hidden limitation: it reasons primarily from sequence, the raw genetic letters of DNA, RNA, and proteins. Two molecules whose sequences look alike are treated as related; two that http://www.streetinsider.com/Globe+Newswire/Most+AI+Drug+Discovery+Reads+the+Genetic+Code.+The+Next+Wave+Is+Learning+to+Read+What+the+Code+Actually+Does./26947782.html Wed, 19 Aug 2026 08:56:00 -0400 ABCL ABCL ABSI ABSI AZN AZN HYFT HYFT LLY LLY http://www.streetinsider.com/Press+Releases/Most+AI+Drug+Discovery+Reads+the+Genetic+Code.+The+Next+Wave+Is+Learning+to+Read+What+the+Code+Actually+Does./26947782.html <p><strong>News Provided by USA News Group on behalf of MindWalk Holdings Corp.</strong></p><p align="left">NEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Tuhl8SoGdqXkIoZcmiFpyrNVstQDwhTHtEEDZyhvi4W7dn-jnhNRtC8cmX1UMw-F3MAMiRzcTRtl5HibqcpvgSSrc-L333VVG8_-f6NSlyo=" rel="nofollow" target="_blank">USA News Group</a><strong> News Commentary - </strong>Artificial intelligence has become the most talked-about tool in drug discovery, promising to compress the years and billions of dollars it takes to turn a biological insight into a medicine. But most of the AI now aimed at biology shares a hidden limitation: it reasons primarily from sequence, the raw genetic letters of DNA, RNA, and proteins. Two molecules whose sequences look alike are treated as related; two that http://www.streetinsider.com/Press+Releases/Most+AI+Drug+Discovery+Reads+the+Genetic+Code.+The+Next+Wave+Is+Learning+to+Read+What+the+Code+Actually+Does./26947782.html Wed, 19 Aug 2026 08:56:00 -0400 ABCL ABCL ABSI ABSI AZN AZN HYFT HYFT LLY LLY